0001213900-18-001471.txt : 20180209 0001213900-18-001471.hdr.sgml : 20180209 20180208183514 ACCESSION NUMBER: 0001213900-18-001471 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180209 DATE AS OF CHANGE: 20180208 EFFECTIVENESS DATE: 20180209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cellect Biotechnology Ltd. CENTRAL INDEX KEY: 0001671502 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-305248 FILM NUMBER: 18587019 BUSINESS ADDRESS: STREET 1: 23 HATA'AS STREET CITY: KFAR SABA STATE: L3 ZIP: 44425 BUSINESS PHONE: 97299741444 MAIL ADDRESS: STREET 1: 23 HATA'AS STREET CITY: KFAR SABA STATE: L3 ZIP: 44425 FORMER COMPANY: FORMER CONFORMED NAME: Cellect Biomed Ltd. DATE OF NAME CHANGE: 20160406 D 1 primary_doc.xml X0708 D LIVE 0001671502 Cellect Biotechnology Ltd. 23 HATA'AS STREET KFAR SABA L3 ISRAEL 41444 972 99741444 ISRAEL T.R.F. Capital Ltd. Cellect Biomed Ltd. Corporation true Kasbian Nuriel Chirich 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Shai Yarkoni 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Executive Officer Director Eyal Leibovitz 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Executive Officer Abraham Nahmias 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Ruth Ben Yakar 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Yuval Berman 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director David Braun 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Michael Berelowitz 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Ruhama Avraham 23 Hata'as Street Kfar Saba L3 ISRAEL 44425 Director Pharmaceuticals No Revenues 06b false 2018-01-31 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 3RD FLOOR NEW YORK NY NEW YORK 10022 IL ILLINOIS NJ NEW JERSEY false 3999996 3999996 0 The warrants and shares underlying the warrants were issued in connection with an offering of (i) 484,848 ADSs issued in a registered direct offering, which are not subject to this Form D, and (ii) unregistered warrants to purchase up to 266,667 ADSs. false 3 280000 0 H.C. Wainwright, LLC is also entitled to non-accountable expense reimbursement of $25,000 and warrants to purchase 24,242 ADSs exercisable at $10.31 per ADS immediately for a period of one year from the date of filing an effective registration statement. 0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers false Cellect Biotechnology Ltd. /s/ Eyal Leibovitz Eyal Leibovitz Chief Financial Officer 2018-02-08